Zilbrysq^®

Europe

In Europe, ZILBRYSQ^® (zilucoplan) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Prescribing information Europe

ZILBRYSQ® SmPC (Sourced from www.ema.europa.eu)

USA

In the U.S. ZILBRYSQ® (zilucoplan) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive.

Prescribing information USA

ZILBRYSQ® (zilucoplan) injection, for subcutaneous use
April 2024